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Abstract
Background: Deciphering host responses contributing to dengue shock syndrome (DSS), the life-threatening form of acute
viral dengue infections, is required to improve both the differential prognosis and the treatments provided to DSS patients,
a challenge for clinicians.
Methodology/Principal Findings: Based on a prospective study, we analyzed the genome-wide expression profiles of
whole blood cells from 48 matched Cambodian children: 19 progressed to DSS while 16 and 13 presented respectively
classical dengue fever (DF) or dengue hemorrhagic fever grades I/II (DHF). Using multi-way analysis of variance (ANOVA) and
adjustment of p-values to control the False Discovery Rate (FDR,10%), we identified a signature of 2959 genes
differentiating DSS patients from both DF and DHF, and showed a strong association of this DSS-gene signature with the
dengue disease phenotype. Using a combined approach to analyse the molecular patterns associated with the DSS-gene
signature, we provide an integrative overview of the transcriptional responses altered in DSS children. In particular, we show
that the transcriptome of DSS children blood cells is characterized by a decreased abundance of transcripts related to T and
NK lymphocyte responses and by an increased abundance of anti-inflammatory and repair/remodeling transcripts. We also
show that unexpected pro-inflammatory gene patterns at the interface between innate immunity, inflammation and host
lipid metabolism, known to play pathogenic roles in acute and chronic inflammatory diseases associated with systemic
vascular dysfunction, are transcriptionnally active in the blood cells of DSS children.
Conclusions/Significance: We provide a global while non exhaustive overview of the molecular mechanisms altered in of
DSS children and suggest how they may interact to lead to final vascular homeostasis breakdown. We suggest that some
mechanisms identified should be considered putative therapeutic targets or biomarkers of progression to DSS.
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Introduction
Acute dengue virus infections are a major public health problem
for many tropical and sub-tropical countries and an increasing risk
for the worldwide population [1]. Symptomatic infections occur
under a spectrum of diseases ranging from classical dengue fever
(DF) to the most severe life-threatening dengue shock syndrome
(DSS), a leading cause of childhood hospitalisation and death in
endemic countries with limited health resources [1,2].
DSS is regarded as a vascular disease involving a complex
interplay between virus, whole blood cells and microvascular
territories [3,4], and thought to result largely from an aberrant host
response to infection. As for other major systemic diseases, a
detrimental cytokine storm is thought to be central to the systemic
microcirculatory failure and massive plasma leakage leading to
cardiovascular decompensation characterizing DSS [5]. However,
controversies exist regarding the nature of pathogenic host immune
responses supporting this life-threatening syndrome [6–8]. Indeed,
reactivation of cross-reactive memory T lymphocytes and increased
infection of monocytes mediated by cross-reactive antibodies
acquired during previous infections by distinct dengue virus
serotypes, are the main hypothetic mechanisms proposed to explain
the putative cytokine storm leading to plasma leakage [5,9].
However, those hypothesis fail to explain the occurrence of DSS
in patients having primary dengue infection and their relevance to
the pathophysiology of DSS disease is discussed [8,10].
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differentiating uncomplicated dengue infections from severe ones
has led to the identification of a diversity of cytokines, chemokines,
endothelial agonists or soluble endothelial molecules [11–18].
However, discrepancies in definition of dengue severity, variability
in patients cohorts characteristics, as well as in techniques and
markers investigated, have impaired the identification of reliable
sets of DSS biomarkers and the possibility to get a global overview
of biological markers altered during DSS.
Understanding the molecular basis of DSS and identifying
relevant DSS biomarkers thus remains a major challenge [5,6].
Indeed, DSS occurs by the end of the acute infection in only a
fraction of dengue-infected patients and current severity criteria,
based on the 1997 World Health Organization (WHO) classifi-
cation of dengue severity, fail to predict a significant proportion of
patients who progress to life-threatening DSS [19–21]. Attempting
to decipher molecular mechanisms underlying DSS by analyzing
circulating whole blood cell genome-wide expression profiles is a
relevant approach regarding the study of other systemic
inflammatory syndromes, where a cognate cross-talk between
endothelial vascular cells and blood cells occurs [22–24]. Whole
blood represent a highly informative while complex cellular
sample, that may reflect host pathophysiological responses ongoing
at the time of blood sampling [22]. Furthermore, whole blood cells
are easy to collect and store during field studies on large cohorts,
reducing samples volumes required and limiting technical bias due
to cell purification. However, due to the high cellular complexity
of whole blood cells samples, whole gene expression patterns
should be carefully analyzed and deciphered to allow returning to
an integrative view of the molecular mechanisms altered during
the pathophysiological process studied [25].
Such a bench-to-bedside medical research has gained more and
more interest in the recent years. Indeed, it allowed improving the
understanding of pathophysiological processes underlying systemic
critical illnesses such as sterile and non sterile systemic inflamma-
tory responses syndromes (SIRS), allowing the identification of
relevant disease biomarkers and of new putative therapeutic
targets [22–24,26].
Genome-wide expression studies aimed at deciphering molec-
ular responses altered in the whole blood cells of adults [27] and
children DSS patients [28] have been implemented recently by
colleagues. They reported a decreased IFN type I-induced
response and a benign transcriptional response at the time of
cardiovascular decompensation [27,28], but failed in identifying
biological pathways relevant to DSS pathophysiology and
particularly inflammatory ones that could sustain microvascular
dysfunction [28].
We report here the results of a prospective study comparing the
whole blood genome-wide expression profiles of 48 matched
Cambodian children recruited during the huge 2007 dengue
outbreak who presented with classical dengue fever (DF), dengue
hemorrhagic fever grades I/II (DHF) or dengue shock syndrome
(DSS), according to the 1997 WHO classification of dengue
severity [29]. Based on careful study design and statistic treatment
of microarrays data, we identified a large and highly relevant gene
signature of DSS never reported before, that discriminates DSS
children from paediatric patients with DF or DHF grades I/II,
who did not present severe clinical complications. Using an
integrative analysis of the gene patterns altered in DSS children,
we deciphered part of the complex interactive molecular processes
occurring during DSS, highlighting similarities between DSS and
other major inflammatory processes. Finally, we identified
unexpected pro-inflammatory innate immune responses activated
in the whole blood cells of DSS children that may play a major
role in DSS pathophysiology. The implications of present findings
to the improvement of DSS prognosis and treatment are discussed.
Materials and Methods
Ethics statement
The global study and all protocols presented here were
approved by the national Cambodian ethical committee. Written
informed consent was obtained from the legal guardians of each
child. To ensure strict anonymity regarding the patients, samples
were encoded as PLxxx (Plasma Leakage).
Patients and clinical data
Inclusion criteria retained were: age (1 to 15 years old); positive
diagnosis of acute dengue infection assessed by different methods;
absence of known chronic inflammatory disease or ongoing acute
co-infection at the time of inclusion.
An eligible cohort of 83 dengue-infected children hospitalised at
the Kampong Cham provincial hospital, Cambodia, was prospec-
tively enrolled from July to September 2007 during the huge 2007
dengue outbreak in Cambodia, characterized by a high number of
DSS cases.
Children diagnosed with acute dengue infections were classified
at admission as classical dengue fever (DF), dengue hemorrhagic
fever (DHF) or dengue shock syndrome (DSS) based on the 1997
WHO criteria [29]. Clinical and biological follow-up was done
daily for each hospitalised patient. DSS patients were admitted to
hospital intensive care unit where they received appropriate fluid
resuscitation and were monitored for vital parameters. Children
who required blood transfusion were not included in the study.
To increase the probability to identify gene signatures specific of
DSS, we chose to include only symptomatic dengue-infected
classified DF, DHF and DSS, but no healthy or non-dengue
children in the present study. This is based on the rationale that
comparing DF, DHF and DSS patients together should improve
the probability to identify a DSS-specific gene signature, while
including an external non dengue control group should increase
the probability to identify a general dengue-related signature but
should be less powerful at identifying a signature of severe dengue
disease.
DF, DHF and DSS patients whole blood samples selected for
the present study corresponded to comparable duration of illness
after onset of fever: all were collected within a window of time
comprised between 3 days and 7 days after onset of fever (being
considered day 0). For most DSS patients, this generally
corresponded to the day of cardiovascular decompensation (shock)
or the day after, except for 3 (PL017, PL033, PL047) and 2 DSS
(PL005, PL101) for whom blood was collected respectively 2 and 3
days after onset of shock.
Patients’ samples selected for the present study were also
carefully matched for age, gender, viral serotype (when identified)
and immunological status (primary or secondary, according to
reference assays described in diagnosis methods) towards dengue
infection.
Diagnosis assays carried out as described thereafter, indicated
that about 90% of all dengue-infected children had secondary
infection.
Dengue diagnosis and immunological status
All diagnosis assays were carried out at the Institut Pasteur in
Cambodia, the National Reference Center for arboviral diseases in
Cambodia. IgM capture ELISA and Hemagglutination-inhibition
were performed on paired sera collected at admission and at
discharge, and systematically tested for both dengue and Japanese
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described previously [30]. Virus isolation was carried out on
earliest serum samples by inoculating permissive C6/36 and
VERO E6 cells, followed by serotype-specific immunofluorescence
[30]. Viral RNA was detected in specimens collected at early stage
of the disease using a nested RT-PCR [31]. Primary or anamnestic
‘‘secondary’’ antibody response indicating previous infections by
dengue viruses was determined from paired serum samples by
hemagglutination-inhibition assay. Interpretation followed WHO
recommendations [29].
Blood sample preparation
Whole blood samples (2.5 ml) were collected on PAXgene
TM
Tubes (PreAnalytiX
TM) further stored at 280uC, before being sent
to France in dry ice. Extraction of series of 24 matched samples
(DF, DHF and DSS) was done using PAXgene
TM Blood RNA kits
(PreAnalytiX
TM) rapidly after collection. Purified total RNAs kept
at 280uC were processed for hybridization on genome-wide DNA
microarrays within one month.
cRNAs preparation and microarrays hybridization
All RNAs were checked for integrity using the 2100 BioAna-
lyzer (Agilent Technologies) and quantified using a ND-1000
spectrophotometer (NanoDrop Technologies). Cyanine-3-labeled
cRNA was generated from 0.3 mg of RNA using the One-Color
Low RNA Input Linear Amplification kit (Agilent) according to
the manufacturer’s instructions, followed by purification on
RNAeasy column (QIAGEN). All amplified cRNAs were checked
for dye incorporation, cRNA yield and amplification profile. Only
those fitting all quality criteria were fragmented for further
hybridization on microarrays. Samples from DF, DHF and DSS
patients were then carefully matched and hybridized onto Agilent
Whole Human Genome (4644K) Oligo Microarrays (G4112F).
Microarrays were scanned using an Agilent DNA microarray
scanner G2505B.
Microarray data analysis
All microarray data is MIAME compliant and the raw and
normalized data have been deposited in the MIAME compliant
database Gene Expression Omnibus [32] (GEO Series accession
number GSE17924 http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE17924).
Individual microarray quality was evaluated based on QC
report, pair-wise MA-plots, and box plots. Intra-array normaliza-
tion of raw signals from the 48 microarrays was done using
Feature Extraction software 9.1.3.1 (Agilent). Microarrays nor-
malized data were further exported into the Limma package [33],
for inter-array normalization using the quantile method [34].
Statistical analysis were was performed using the TIGR MeV
(MultiExperiment Viewer) v 4.4 software (http://www.tm4.org/
mev.html), and the GeneANOVA program [35]. Multi-way
ANOVA model was implemented: first, to identify differentially
regulated genes when accounting for the multiple sources of
variation in the microrray experiment; second, to evaluate the
effect of the main variable, disease phenotype, relatively to that of
other putative confounding variables such age, gender, duration of
illness or microarray technical variability (independent extractions
or hybridizations). Local ANOVA further determined the
contribution of each covariate on the expression level of each
gene. Multiple test correction was further carried out using the
false discovery rate (FDR) method [36]. Cluster [37] and Tree
View softwares [38] were used for unsupervised hierarchical
clustering. Iterative SVM (Support Vector Machine) method
associated with leave-one-out cross-validation [39] was used to
assess the robustness of DSS-gene signature.
Real-time PCR validation of genes over and under-
expressed in DSS patients
Briefly, total RNA extracted from whole blood samples was
reverse-transcripted using the High Capacity cDNA RT kit
(Applied Biosystems Inc) and random primers. Real-time PCR
were carried out using the FastStart Universal Probe Master
(ROX) (Roche) and real-time PCR primers designed using the
Universal Probe Library (UPL) Assay Design Center (Roche).
Amplification products were run on an ABI-PRISM 7900HT
(Applied Biosystems). Cycle threshold Ct values were automati-
cally calculated and value obtained for each gene amplified was
normalized by subtracting the Ct corresponding to amplification
of the HPRT1 gene (DCt) for the same sample. Correlation
between DCt values obtained by real-time PCR and correspond-
ing expression values from microarrays was estimated using
Spearman correlation coefficient.
Comprehensive overview of functional patterns altered
during DSS
Bio-informatics-based analysis using the demonstration version
7.1 of Ingenuity Pathway Analysis software (IPA; IngenuityH
Systems, www.ingenuity.com) associated with manual and littera-
ture-based analysis was carried out to identify the most relevant
functional processes associated with the identified DSS gene
signature. This was done by combining most informative canonical
pathways identified using IPA, genes having the strongest
association with the disease phenotype based on ANOVA analysis,
and similarities to molecular patterns altered in other systemic
inflammatory processes associated with endothelial dysfunction.
Results
Patient characteristics
To identify gene patterns specifically altered in DSS patients, we
compared three groups of carefully matched paediatric patients
representing the main clinical forms of symptomatic dengue
infections DF (n=16), DHF (n=13) and DSS (n=19), according
to the 1997 WHO classification criteria of dengue severity [29].
Altogether, DF, DHF and DSS represent different subtypes of the
disease phenotype variable, further considered in this study. The
clinical characteristics and values of haematological parameters
are presented in table 1 (median values from each patient group)
and table S1 (individual values from each of the 48 patients
included). Supportive treatment provided to DSS patients are
mentioned. As indicated, DSS children had significant lower
relative neutrophil counts (median values / DF: 3900; DHF: 3950;
DSS: 2500; p-value: 0.03; Kruskal Wallis test).
Unsupervised hierarchical clustering discriminates DSS
children from DF/DHF ones, revealing a DSS-gene
signature
Since microarray data analysis can be affected by a number of
bias [40], we put a particular care on study design and analysed
data from the 48 normalized microarrays using multi-way analysis
of variance (ANOVA) [41]. Indeed ANOVA evaluates the
statistical probability (p-value), for each individual gene, that a
difference in expression between the three patient groups could
have been observed by chance. This allows revealing genes that
show even small but highly significant changes in expression,
regarding the studied phenotype.
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between DF, DHF and DSS groups were generated using different
false discovery rate (FDR) ranging from 0.05 up to 10%. Indeed,
low FDR provide more stringent statistical filter while they reduce
the number and thus the enrichment of genes differentially
expressed. At the opposite, higher FDR, while statistically
accepting a higher number of false positive genes, also provide
larger and enriched gene lists that should be more informative
when searching to identify molecular pathways. Based on this
rationale, we chose to work using the gene list generated at FDR
10 after we verified by a different statistical method currently used
for the analysis of microarrays data, SAM (Significant Analysis of
Microarray) [33], that most significant genes were commonly
found by the two types of analyses (data not shown). The gene list
generated at FDR10 included 2959 genes differentially expressed
between DF, DHF and DSS patients groups (Table S2).
The biological relevance of those differentially expressed
genes was assessed using local ANOVA that allows evaluating
the contribution of the main variable, disease phenotype, and
that of other putative confounding variables related to patients
(age, gender, day of blood sampling, viral serotype) and to
technical steps (effect of independent RNA extractions,
amplifications and hybridization) on variations of expression
levels of those 2959 genes. This confirmed that the disease
phenotype strongly influenced the variations of expression of
the 2959 genes differentially expressed between the three
patient groups, reinforcing the biological significance of this set
of genes (Table S2).
Unsupervised hierarchical clustering based on the 2959 gene
signature identified was then applied to the 48 children gene
expression profiles. This allows clustering the patients whose gene
expression profiles are the more similar independently of their
disease phenotype subtype. As a result, the 48 patients expression
profiles were organized in two major subsets (Figure 1): subset 1
(first dendrogram branch) includes both DF and DHF patients
without distinction; subset 2 (second dendrogram branch)
encompasses a sub-group (2a) of DF and DHF patients, and a
distinct sub-group (2b) including 17 out of the 19 DSS patients,
whatever they received or not plasma infusion, revealing a ‘‘DSS-
gene signature’’ common to most DSS patients. Some few patients
clustered however in unexpected subsets: two DSS patients
(PL005, PL101) had gene expression profiles closer to those of
the DF/DHF 2a subset, while one DF patient (PL064) and three
DHF patients (PL037, PL058, PL070) gene expression profiles
clustered within the DSS 2b subset.
We confirmed the robustness of the DSS-gene signature using
the iterative Support Vector Machine (SVM) classifier learning
method [39], which reclassified all the 19 DSS patients together.
Table 1. Clinical and biological characteristics of DF, DHF and DSS patient groups at the time of hospital admission.
DF (n=16) DHF (n=13) DSS (n=19)
Patients characteristics
gender, male n (%) 7 (43%) 4 (31%) 7 (37%)
age, median (IQR), years 8 (4–9) 7 (5–8) 8 (7–9)
weight, median (IQR), kg 18 (13–20) 15 (14–18) 19 (15–23)
hospital admission, median (IQR), day after onset of fever (D0) 2 (1–3) 2 (2–3) 4 (3–4)
Dengue status
viral serotype, n (DENV-1/DENV-2/DENV-3/DENV-4/unknown) 4/2/8/1/1 1/1/10/1/0 1/1/10/0/7
immunological status, secondary infections, n (%) 14 (88%) 12 (92%) 18 (95%)
Clinical manifestations
tourniquet test (pos/neg/not done) (%) 56%/44%/0% 54%/38%/8% 37%/32%/31%
hepatomegaly, n (%) 3 (19%) 6 (46%) 17 (89%)
gastro-intestinal bleeding, gingivorragy, hematemesis, melena,
n (%)
0 1 (8%) 6 (32%)
Blood pressure
heart frequency, median (IQR), pulse per minute 113 (100–124) (n=14
a) 120 (112–120) Not perceptible (n=15
a)
pulse pressure, median (IQR ), mm Hg 40 (30–45) 30 (30–40) 15 (10–20) (n=15
a)
Haematological parameters
thrombocytopenia (platelet count ,100000/mm
3), % 15% (n=14
a) 55% (n=11
a) 94% (n=17
a)
hematocrit, median (IQR), % 36.5 (35–39) (n=14
a) 39.75 (38–42) (n=12
a) 42.5 (38–45) (n=18
a)
hemoconcentration (hematocrit .20%), n (%) 1 (6%) 3 (23%) 17 (89%)
white blood cells, median (IQR), number/mm
3 6600 (5500–9900) (n=13
a) 6450 (6200–7400) (n=10
a) 6900 (4800–6900) (n=17
a)
neutrophils, median (IQR), number/mm
3 3900 (2900–7600) (n=13
a) 3950 (3500–4200) (n=10
a) 2500 (2200–3800)(n=17
a)
lymphocytes, median (IQR), number/mm
3 1600 (1400–2100) (n=13
a) 1850 (1500–1900) (n=10
a) 2200 (1500–3200) (n=17
a)
Supportive medical care
oxygen supplementation, n (%) 0 0 15 (79%)
perfusion of colloid (dextran 40), n (%) 0 0 14 (74%)
perfusion of human plasma, n (%) 0 0 8 (42%)
DENV, dengue virus; DF, dengue fever; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; IQR, interquartile range; n, number.
an=x : with x : number of patients for which the data is available.
doi:10.1371/journal.pone.0011671.t001
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focusing on nine genes strongly associated with the DSS-gene
signature, using 15 patients samples (five from each disease
phenotype subtype: DF, DHF and DSS). Results obtained strongly
correlate microarray data (Figure S1).
DSS-gene signature analysis identifies a diversity of
genes and canonical molecular pathways related to
immunity, inflammation and host metabolism
Filtering genes from those having the highest to the lowest
statistical association with the disease phenotype variable (Table
S2), relying on results from multi-way and local ANOVA revealed
that the individual genes having the strongest association with the
DSS phenotype subtype are, for a large part, related to innate
immunity, inflammation and host lipid metabolism, a finding
confirmed when the whole 2959 genes of the DSS-gene signature
were processed through the knowledge-based IPA software.
Indeed, IPA analysis identified that 163 canonical pathways
were significantly associated with those genes (data not shown)
with a large proportion of immune-related pathways in the first
top 30 (Figure 2). In particular, several under-expressed but
partially redundant signaling canonical pathways related to T
lymphocyte activation were identified, of which the T cell receptor
(TCR) signaling pathway (Figure 3), which has the strongest
association with the DSS-gene signature. Interestingly, a number
of metabolic pathways, and particularly of lipid-signaling path-
ways, were significantly represented among the 163 DSS-related
canonical pathways.
When comparing our results to those of colleagues who reported
gene or protein signatures associated with DSS, we identified some
transcripts encoding proteins considered putative markers of
severe dengue. This includes non exhaustively the acute phase
pentraxin-related protein PTX3 [15], the anti-inflammatory IL-10
[11] or the pro-inflammatory IL-18 [12] cytokine transcripts that
have increased abundance in the DSS-gene signature, while
having intermediate to low statistical association with the disease
phenotype variable according to the multi-way ANOVA (Table
S2).
IFN type I-related transcripts, of which abundance was shown
to be decreased in DSS patients by others [27,28,42], represented
only a limited number of genes associated with the DSS-gene
signature. This was confirmed by the IPA analysis that did not
identify IFN type I-related pathways among those strongly
associated with the DSS-gene signature (Figure 2).
DSS is associated with impaired expression of T and NK
cell-related genes but increased expression of anti-
inflammatory and repair/remodeling transcriptional
responses
Integrative analysis of the most significant individual genes and
canonical pathways extended the finding that a large and diverse
set of genes related to T but also to NK lymphocyte activity is
Figure 1. Unsupervised hierarchical clustering of whole blood
cells expression profiles from the 48 dengue-infected children.
The clustering is based on the 2959 gene list (3515 clones, detailed in
Table S2) discriminating dengue fever (DF), dengue hemorrhagic fever
(DHF) and dengue shock syndrome (DSS) patients. Each row represents
a single transcript and each column represents a patient’s sample. Color
scale indicates the range of gene expression: black indicates median
expression level, red greater expression, green lower expression. The 2
patient subsets identified are indicated. PLxxx, code relative to one
patient. Black star: DSS patient sampled 3 days after shock. Orange star:
Patients who received perfusion of human plasma before collection of
blood samples.
doi:10.1371/journal.pone.0011671.g001
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counterparts (Table 2; non exhaustive list; individual p-values
available in Table S2; and Figure 3). Those genes are critical to a
number of T and NK-cell functions, including T and NK cell
differentiation, receptor signaling, activation and proliferation,
cytotoxic functions or recruitment of lymphocytes to peripheral
tissues. Since lymphocyte counts did not differ between the DF,
DHF and DSS children (p=0.428; Kruskal Wallis test), we
searched whether genes encoding factors regulating negatively T
and NK functions were over-expressed in the DSS-gene signature.
We identified that the two genes having the strongest association
with the disease phenotype variable, encode two major immuno-
modulatory factors, the microsomal prostaglandin E synthase
(PTGES/Agilent clone number A-24-P478940) and the comple-
ment regulatory protein CRIg/VSIG4, considered potent negative
regulators of T and NK cell responses [43–45]. The decreased
abundance of NFkB signal transduction-related transcripts
(Table 2), already reported in DSS patients by others [46], might
be related to impaired expression of T and NK cell-related genes.
Our analysis also revealed that DSS whole blood cells from
children over-expressed an enriched pattern of anti-inflammatory
and repair/tissue remodeling genes (Table 3; non exhaustive list;
individual p-values available in Table S2). Over-expressed anti-
inflammatory genes identified encode molecules with diverse
functions: the anti-inflammatory cytokine IL-10, a putative marker
of severe dengue [11], serine proteases and metalloprotease
inhibitors, IL-1b cytokine decoy receptor, free heme scavenger
molecules, or complement-regulating receptors. Repair and
remodeling genes over-expressed in the DSS-gene signature also
encode a diversity of molecules: the MMP-9, a matrix metallo-
protease with key role in tissue remodeling and a candidate to
dengue plasma leakage [47], the extracellular matrix molecules
fibronectin, versican and collagens, the angiogenin and VEGF
[17] endothelial agonists as well as the arginase 1 repair enzyme,
which competes with the endothelial NOS (NOS3) for L-arginine
biodisponibility [48].
Thus, DSS children whole blood cells have a global decreased
abundance of T and NK cell-related transcripts but an increased
abundance of anti-inflammatory and repair/remodeling tran-
scripts at the time of cardiovascular decompensation.
Pro-inflammatory innate defense and host-lipid
metabolism-related transcriptional responses are
activated in DSS children
When searching for pro-inflammatory gene patterns that may
be relevant to DSS pathophysiology and particularly to systemic
inflammation and vascular dysfunction, we identified three major
pro-inflammatory gene patterns. Interestingly, all are related to
innate defense and host lipid metabolism, and considered major
pathogenic mechanisms in other systemic inflammatory diseases.
As shown in table 4 (non exhaustive list; individual p-values
available in Table S2), the first one is defined by a set of over-
expressed genes strongly associated with the disease phenotype
subtype DSS that encode highly pro-inflammatory microbicidal
peptides and enzymes. This pattern includes non exhaustively the
alpha defensins DEFA1, DEFA3 and DEFA4, the cathelicidin
(CAMP) and lactoferrin (LTF) peptides, the neutrophil enzymes
Figure 2. Top 30 canonical pathways identified from the DSS-gene signature using Ingenuity Pathway Analysis software. The
significance of the association between data set and canonical pathway was estimated by the p-value (Fischer’s exact test; left axis) and the ratio
(right axis) of genes that maps to each canonical pathway.
doi:10.1371/journal.pone.0011671.g002
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sin G and neutrophil elastase (ELANE). Transcripts encoding the
potent pro-inflammatory calgranulins proteins S100A8/9 and
S100A12, characteristic of granulocyte neutrophil activity [51]
and involved in a diversity of inflammatory diseases [56], as well as
the granulocyte-related metalloprotease MMP8 are also over-
expressed. Increased abundance of those transcripts cannot be
explained by increase in granulocyte count, since DSS patients
have lower relative granulocyte counts than DF and DHF
counterparts (median values/DF: 3900; DHF: 3950; DSS: 2500;
p-value: 0.03; Kruskal Wallis test), thus reflecting more likely
cellular activation. Altogether those results show that a transcrip-
tional pattern of innate defense genes is activated in the whole
blood of DSS children.
The second pro-inflammatory gene pattern identified is typical
of altered homeostasis of cholesterol in monocytes/macrophages
that characterises inflammatory lipid-laden monocytes/macro-
phages (lipid-laden Mo/Mac), a subtype of foam cells initiating
vascular lesions in metabolic inflammatory diseases [57–59]
(Table 5; non exhaustive list; individual p-values available in
Table S2). Since the PPARG gene, which encodes a nuclear-
lipid receptor involved in lipid signaling and lipid-homeostasis
in inflammatory lipid-laden Mo/Mac [65], has a very strong
association with the dengue disease phenotype, we searched
whether other genes involved in cholesterol homeostasis in Mo/
Mac had altered expression in the DSS-gene signature.
Remarkably, we found a large lipid-laden Mo/Mac-related gene
expression pattern characterized in particular by a higher
abundance of transcripts encoding the key scavenger receptors
of modified low density lipoproteins OLR-1, CD36 and MSR1,
but a decreased abundance of transcripts encoding critical
cholesterol transporters such as the NPC1 [66] or the ABCA1-
Figure 3. T Cell Receptor Signaling canonical pathway from Ingenuity Pathway Analysis. Genes in green and red are respectively under-
and over-expressed in the DSS-gene signature. Genes in white are other genes present in the canonical pathway but absent from the DSS-gene
signature. DSS: Dengue Shock Syndrome.
doi:10.1371/journal.pone.0011671.g003
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cholesterol from Mo/Mac. Other lipid-laden cells-related genes
also have altered expression in the DSS-gene signature. In
particular, the PPARA gene that negatively regulates the
formation of lipid-laden Mo/Mac [87] has decreased abundance
in DSS patients. At the opposite, transcripts encoding the
chitinase 1, a marker of pro-inflammatory lipid-laden Mo/Mac
[73], and the FABP4, SOCS6, RETN and IRS2 proteins
involved in lipid-laden Mo/Mac-induced insulin-resistance and
compensatory response [68–72], have all increased abundance,
also strongly supporting a biological signature of foam cells.
Interestingly, the PCSK9 transcript, which encodes a secreted
protein that decreases the recycling of LDL to the liver by
inducing the degradation of liver LDL receptors [74], is also over-
expressed in the DSS signature and highly associated with the
disease phenotype.
Thus, a gene expression pattern similar to that characterizing
lipid-laden monocytes, is activated in the whole blood cells of DSS
children at the time of cardiovascular decompensation.
The third pro-inflammatory gene pattern associated with
the DSS-gene signature is characteristic of the metabolic pro-
inflammatory arachidonic-acid pathway, one of the lipid
metabolic pathways identified through IPA. As shown in table 5,
the gene encoding the upstream cytosolic phospholipase
Table 2. T lymphocytes and NK cells-related genes present in the DSS-gene signature.
Function Genes P-value Var.
a (%)
Th1 differentiation RUNX3, STAT4, TBX21 ,0.00001 to 0.00242 25 to 42
Th2 differentiation GATA3, STAT5A 0.00003 to 0.00225 17 to 32
Cytotoxic T lymphocyte functions CTSW, PRF1 0.00005 to 0.00231 21 to 33
T lymphocyte activation IL2RB, IL2RG 0.00014 to 0.00039 29 to 35
Cooperation with antigen-presenting cells CD40LG 0.00105 21
Recruitment and interaction of T lymphocytes with endothelium ITGAL, XCL1, XCL2 ,0.00001 to 0.00214 20 to 33
Inhibitory NK cell receptors KLRD1 0.00001 31
Activating NK cell receptors NCR1, NCR3, CD160 ,0.00001 to 0.00069 28 to 39
Cytotoxic molecules GZMM ,0.00001 32
Receptors for NK cells homing to peripheral tissues S1PR5 ,0.00001 48
Differentiation factors of NK cells FLT3LG, IL15, IL17C, KITLG 0.00088 to 0.00774 13 to 21
Suppression of T lymphocytes and NK cells response PTGES, VSIG4 ,0.00001 60 to 63
NFkB-related genes IRAK3, TNIK, RELA, NFKBIB, TRAF1,
TRAF2, TRAF6
0.00001 to 0.00506 9 to 31
HUGO gene names are indicated. When genes were represented by several clones on the microarray, p-value and variance medians were calculated. Genes in regular
and bold are respectively under- and over-expressed in dengue shock syndrome patients.
apercentage of variance associated to disease phenotype.
doi:10.1371/journal.pone.0011671.t002
Table 3. Anti-inflammatory, tissue remodeling and repair genes present in the DSS-gene signature.
Function Gene Symbol P-value Var.
a (%)
Anti-inflammatory genes
immunoregulatory molecules IL10 0.00430 20
anti-proteases SERPINB2, SERPINB8, SERPINB10, SLPI ,0.00001 to 0.00081 19 to 49
metalloproteinase inhibitor TIMP1 0.00183 19
decoy receptor IL1R2 0.00077 30
free-heme scavenger molecules CD163, HP, HMOX1 ,0.00001 to 0.00064 26 to 46
complement regulatory molecules CD55, VSIG4 ,0.00001 to 0.00096 24 to 60
Tissue remodeling and repair genes
metallopeptidase MMP9 0.00001 33
extracellular matrix components COL1A2
b, COL8A2
b, COL14A1
b, COL17A1
b, FN1
b, SDC1
b,
VCAN
b
,0.00001 to 0.00309 18 to 34
pro-angiogenic factors ANG, VEGFA 0.00004 to 0.00236 25 to 30
others ARG1, NOS3 ,0.00001 to 0.00054 18 to 44
HUGO gene names are indicated. When genes were represented by several clones on the microarray, p-value and variance medians were calculated. Genes in regular
and bold are respectively under- and over-expressed in dengue shock syndrome patients.
apercentage of variance associated to disease phenotype.
bDanger-associated molecular pattern (DAMP) activity.
doi:10.1371/journal.pone.0011671.t003
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membrane phospholipids [78], is over-expressed. Similarly, most
downstream key enzymes from the COX-2 and 5-LOX sub-
pathways involved in the final synthesis, conversion and transport
of inflammatory eicosanoids lipid mediators, are over-expressed.
In particular, the transcript encoding the inducible microsomal
prostaglandin E synthase PTGES that catalyzes the conversion of
prostaglandin PGH2 to PGE2 in the COX-2 sub-pathway, and
thought to play a pathogenic role in a number of inflammatory
processes [88] is significantly increased and has the highest
statistical association with the disease phenotype (62% of gene
variance explained by the disease phenotype according to multi-
way ANOVA). At the opposite the PTGDS transcript, which
encodes the anti-inflammatory prostaglandin D2 synthase, has
decreased abundance, a finding already reported in metabolic
inflammatory processes [89]. Increased abundance of the
transcript encoding the LTA4H enzyme that converts the
LTA4 leukotriene to LTB4 reflects the activation of the 5-LOX
sub-pathway. Finally, transcripts encoding the oxidative enzymes
ALOX15B lipoxygenase [84] and cytochrome P450 epoxygenase
family members [85], involved in the arachidonic acid metabolic
pathway, are also significantly increased in the DSS-gene
signature, also reflecting activation of those sub-pathways during
DSS.
Thus, a transcriptional signature related to the lipid-related
metabolic arachidonic acid pathway is activated in the whole
blood cells of DSS children at the time of cardiovascular
decompensation.
Discussion
Numerous studies have addressed the pathophysiology of
DSS, the more frequent and severe complication of dengue
infections. Despite important findings, only partial understand-
ing of the cellular and molecular processes that may support this
life-threatening syndrome has been obtained, and we still lack a
comprehensive overview of the complete figure of alterations
that contribute to – or reflect – the setting-up of the shock
syndrome. This could allow the improvement of patients’
management and treatment, a major challenge for clinicians.
We designed a study aimed at analysing the quasi-global
transcriptome of whole blood cells from dengue paediatric
patients, looking at every modification that could make sense to
the understanding of the pathogenic process. The capacity of
such an exhaustive approach to identify relevant host responses,
of which unsuspected pathways has been demonstrated in other
systemic inflammatory syndromes such as human sepsis or post-
trauma sterile SIRS [23–25]. We compared the transcriptome
of blood cells from DSS paediatric patients at time of shock to
those of children classified as DF or DHF grades I/II [29]
matched for important variables such as age, gender, immune
status towards dengue infection (primary or secondary infection)
and time of disease evolution after onset of fever. Our study has
produced significant results, further discussed in the context of
DSS pathophysiology.
First, we identify a transcriptional signature of the DSS,
differentiating DSS from the other forms of dengue infection
and characterizing DSS as a unique and specific entity. Giving
particular attention to study design and statistical analysis, we
identify a large and robust gene expression profile of 2959 genes
that discriminates DSS paediatric patients from other dengue
patients, DF or DHF, who did not progress to shock, whatever the
supportive treatment they received. Importantly, DSS children
clustered together whatever they were considered as having
primary or secondary dengue infection, while secondary infections
represented the majority of DF, DHF and DSS children recruited
(see table S1), as expected in hyper-endemic areas. The robustness
of the DSS-associated gene signature was established by showing
that the disease phenotype variable significantly affected expres-
sion levels of all the genes identified (multi-way ANOVA) and
Table 4. Pro-inflammatory innate immunity-related genes present in the DSS-gene signature.
Function Gene Symbol P-value Var.
a (%) Main cellular origin Ref
microbicidal peptides DEFA1
b, DEFA3
b,
DEFA4
b
,0.00001 to 0.00007 0.25 to 0.44 PMN neutro, EpC [49,50]
CAMP
b ,0.00001 0.34 PMN neutro, Mo, mast cells, EpC [49,50]
LTF
b ,0.00001 0.41 PMN neutro, inflammed EpC [50]
calgranulin proteins S100A8
b, S100A9
b ,0.00001 to 0.00014 0.18 to 0.38 PMN neutro, Mo/Mac [51,52]
S100A12
b ,0.00001 0.33 PMN neutro [51]
granulocyte enzymes RNASE2
b 0.00017 0.25 Mo/Mac, Eo, EpC, PMN neutro [53]
MPO
b 0.00024 0.25 PMN neutro, Mo, subtypes of tissue Mac [50]
RNASE3
b ,0.00001 0.29 Eo, Mo, PMN neutro [54]
MMP8 ,0.00001 0.49 PMN neutro [50]
CTSG ,0.00001 0.36 PMN neutro [50]
ELANE ,0.00001 0.39 PMN neutro [50]
pro-inflammatory cytokines and related
molecules
IL18 0.00052 0.21 Kupffer cells, activated Mac, Mo, DC, EpC [55]
IL18BP 0.00710 0.20 T cells, peripheral blood leukocytes, EC [55]
HUGO gene names are indicated. When genes were represented by several clones on the microarray, p-value and variance medians were calculated. Genes in regular
and bold are respectively under- and over-expressed in dengue shock syndrome patients. DC, dendritic cell; EC, endothelial cell; Eo, eosinophil; EpC, epithelial cell; Mac,
macrophage, Mo, monocyte; PMN neutro, polymorphonuclear neutrophil; RAGE, receptor for advanced glycation end products.
apercentage of variance associated to disease phenotype.
bDanger-associated molecular pattern (DAMP) activity.
doi:10.1371/journal.pone.0011671.t004
Molecular Mechanisms of DSS
PLoS ONE | www.plosone.org 9 July 2010 | Volume 5 | Issue 7 | e11671demonstrating the classifying capability of this gene signature using
unsupervised hierarchical clustering and SVM/leave-one-out
methods [35,39,40]. Based on unsupervised hierarchical cluster-
ing, DHF grades I/II patients’ expression profiles appear very
close or indistinguishable from those of DF patients at the same
time of disease evolution, while they group into two heterogeneous
sub-groups (1 and 2b, Figure 1), of which significance should be
investigated. Altogether, the present results highlight the inade-
quacy of the 1997 WHO classification of dengue clinical forms
[19–21], that considers DF and DHF grades I/II as two separate
disease phenotypes, and support the recently proposed classifica-
tion [90].
Two important questions arise about the DSS-associated
transcriptional profile: are the observed modifications of genes
expression the cause or the consequence of the pathology, and
could these modifications have a predictive value? We cannot
definitively answer these questions from the present study, in part
because blood samples were collected at the onset of shock (14 out
of the 19 DSS patients) or after (5 patients). Functional study of
each individual pathway will be required to fully understand the
role of each gene in a complex network of molecular interactions.
The ability of some genes transcripts or genes products to
accurately predict progression to DSS should be evaluated by
multivariate regression models [91] using blood samples collected
before the onset of shock, while this proves to be difficult in the
context of dengue outbreaks [28]. In the present study, we chose to
focus on those of the identified molecular mechanisms that made
the more sense to DSS pathophysiology and systemic vascular
dysfunction, referring to recent findings on the role of innate
immunity in systemic inflammatory processes leading to shock,
multi-organ dysfunction syndromes or other pejorative clinical
outcomes.
Second, while present results confirm some putative DSS-
related biomarkers, it also reveals unreported alterations that make
sense to hypovolemic shock pathophysiology. This reinforces the
ability of a global and ‘‘open mind’’ approach to identify
molecular processes relevant to the studied pathology. Blood cells
transcriptional profiles clearly reveal alterations of different
immune responses and the activation of a large pro-inflammatory
response. A significant proportion of genes of which expression is
modified are related to host innate immunity, lymphocyte
functions and lipid metabolism in particular. This genome-wide
expression analysis also confirms the over-expression of individual
biomarkers previously associated with severe dengue, such as the
acute phase pentraxin-related protein PTX3, the pro-inflamma-
tory IL-18 cytokine or the anti-inflammatory IL-10 cytokine
(Table S2) [11,12,15], providing a more comprehensive overview
of their implication in the pathophysiology of DSS.
Our results differ however from those reported by Long et al in a
genome-wide expression profiling study comparing DSS children
with uncomplicated paediatric patients [28]. This study concluded
on a global ‘‘benign’’ and ‘‘muted’’ immune transcriptional
response but a decreased expression of genes involved in IL-10
and IFN type I-related pathways in DSS children blood cells [28].
Table 5. Pro-inflammatory lipid-related genes present in the DSS-gene signature.
Function Gene Symbol P-value Var.
a (%) Disease Ref
Lipid-laden Mo/Mac-related genes
scavenger receptors of modified
LDL in Mo/Mac
OLR1, CD36, MSR1 ,0.00001 to 0.00013 0.21 to 0.32 metabolic diseases [60–64]
lipid nuclear receptor/signalisation
by lipids
PPARG, PPARA 0.00007 to 0.00732 0.21 to 0.34 metabolic diseases [65]
efflux of modified cholesterol from
Mo/Mac
NPC1 0.00005 0.32 Niemann-Pick disease, atherosclerosis [66,67]
ABCA10 0.00016 0.14 none
migrating Mo/resident Mac
chemokine receptors
CCR2, CX3CR1 0.00001 to 0.00099 0.22 to 0.40 atherosclerosis [57]
other lipid-laden-related Mo/Mac
genes
FABP4, SOCS6, RETN,
IRS2
,0.00001 to 0.00092 0.20 to 0.26 metabolic diseases [68–72]
CHIT1 ,0.00001 0.48 Gaucher’s disease, atherosclerosis [73]
PCSK9 0.00001 0.42 familial hypercholesterolemia [74]
SPP1 ,0.00001 0.49 metabolic and inflammatory diseases [75,76]
anti-oxydant enzymes LCAT, PAFAH2 0.00196 to 0.00461 21 to 26 metabolic diseases [77]
Arachidonic acid pathway-related genes
phospholipase PLA2G4A 0.00003 0.21 rheumatoid arthritis [78]
eicosanoid synthesis enzymes PTGES, LTA4H, PTGDS,
TBXAS1, PTGDR
,0.00001 to 0.00123 0.22 to 0.63 metabolic and inflammatory diseases,
asthma, cancer
[79–82]
leukotrienes convertion enzyme MGST2 0.00003 0.32 none
leukotriene transporter SLCO2B1 0.00010 0.31 asthma [83]
lipid oxidation ALOX15B 0.00011 0.33 atherosclerosis [84]
cytochrome P450 superfamily
enzymes
CYP1B1, CYP2U1,
CYP51A1
,0.00001 to 0.00686 10 to 32 Vascular inflammation [85]
HUGO gene names are indicated. When genes were represented by several clones on the microarray, p-value and variance medians were calculated. Genes in regular
and bold are respectively under- and over-expressed in dengue shock syndrome patients.
apercentage of variance associated to disease phenotype.
doi:10.1371/journal.pone.0011671.t005
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sampling from patients in the course of dengue disease may
explain these differences. Indeed, in our study, two DSS children
had gene expression profiles close to those of uncomplicated DF
and DHF, and clustered within the DF/DHF cluster. Both proved
to be the children from whom blood was sampled three days after
the onset of shock, while the three DSS children sampled two days
after shock onset still exhibited a typical DSS gene expression
profile. This suggests that a shift from a ‘‘severe’’ to an
‘‘uncomplicated’’ transcriptional profile may occur within a very
short time, and could explain the ‘‘uncomplicated’’ and benign
gene immune transcriptional responses reported by Long et al [28].
Differences in strategies and methods used to filter genes
differentially expressed between patients’ groups could also explain
the finding that few IFN type I-related genes but a large diversity
of other pathways were identified in the present study compared to
other transcriptomic studies of DHF or DSS patients. Here, genes
were selected considering only their statistical significance and
their association with the disease phenotype. Differently from
others [27,28,42], no ‘‘fold change’’ cut-off filter was applied since
this non-statistically-motivated criteria selects preferentially genes
prompt to high variations such as the IFN type I-induced genes
[92,93], thus excluding from subsequent bio-informatic analysis a
diversity of transcripts exhibiting more subtle variations but strong
associations and biological relevance with the considered disease
phenotype.
Third, unsuspected mechanisms identified in DSS patients
could contribute importantly to the pathophysiology of this severe
syndrome, as supported by similarities between those DSS-related
alterations and other critical syndromes. Interestingly, a number of
immune, repair-remodeling and metabolic-related related path-
ways are simultaneously altered in the blood cells of DSS children
at the onset of shock. In particular, T and NK lymphocyte
transcriptional responses are globally impaired while genes
implicated in compensatory anti-inflammatory and repair/remod-
eling responses and in innate immune responses are over-
expressed. This highlights the complexity of biological responses
at the time of dengue shock syndrome, and points out similarities
between DSS and other critical syndromes such as severe sepsis, or
post-trauma SIRS that are similarly characterized by depressed T
lymphocyte responses but over-expressed innate immunity
[94,95].
Reduced abundance of a number of T-lymphocyte related
transcripts at the time of DSS may reflect a feed-back mechanism
aimed at limiting an initial early T lymphocyte activation, reported
to occur in patients who further progress to severe dengue [96,97].
Such a negative feed-back may be sustained by the over-expression
of a diversity of anti-inflammatory transcripts in DSS patients’
blood cells at the time of shock. In particular, the two potent
immunomodulating factors prostaglandin E synthase and VSIG4,
which dampen both T and NK lymphocyte responses [43–45] and
have both a strong statistical association with the DSS phenotype,
could have such a negative effect. Based on those observations and
previous clinical reports, the benefit of corticotherapy in DSS
patients might thus be questioned [98,99].
Over-expression in the blood of DSS children of several repair
and remodeling genes encoding extracellular matrix proteins,
vasoactive mediators and matrix metalloproteases such as the
MMP9, likely reflects a compensatory response to inflammatory
insults, and a number of those genes products are now
considered putative biomarkers in systemic inflammatory
syndromes such as severe sepsis [100]. Most proteins encoded
by those genes are indeed secreted by activated immune cells
such as monocytes/macrophages. They may have adverse effects
towards the vascular endothelium when produced in excess,
since they may increase immobilization of inflammatory
mediators at the surface of endothelial cells [101], permeability
of capillaries [102], or induce direct damage to endothelial
tissues [103]. Recently, one of them, MMP9 has been proposed
as a putative candidate in the occurrence of plasma leakage
during dengue infection [47].
While previous transcriptional studies failed to identify pro-
inflammatory gene patterns in the blood cells of DSS patients
[27,28,42], our study is the first one to report that a diversity of
pro-inflammatory transcriptional responses at the interface of
innate immunity, inflammation and host lipid metabolism are
activated at the time of cardiovascular failure. Since those
mechanisms are considered pathogenic in other systemic inflam-
matory diseases where systemic vascular dysfunction does occur,
we suggest that they may altogether contribute to DSS
pathophysiology.
Activation of a pro-inflammatory defence gene pattern in DSS
patients’ blood cells (Table 4) has relevance to the pathophysiology
of systemic vascular dysfunction, since most microbicidal peptides
and enzymes have recognized pro-inflammatory and pathogenic
effects towards vascular endothelial tissues [50]. Among them, the
neutrophil microbicidal peptides alpha defensins and the highly
pro-inflammatory calgranulins proteins S100A8/A9 and S100A12
are now considered putative pathogenic factors in sepsis,
cardiovascular diseases, rheumatoid arthritis or atherosclerosis
[51,56,104]. While neutrophils are considered the main source of
those defence molecules, this cellular origin cannot be established
from the present study due to the cellular complexity of
unfractionnated whole blood samples and to the possibility that
other circulating cell types may express a neutrophil-like
inflammatory repertoire under pathologic conditions [105]. A
putative neutrophil origin of this gene expression pattern is
however supported by the over-expression in DSS patients blood
cells of transcripts encoding other neutrophil-related molecules
such as the MMP8 matrix metalloprotease, CEACAM-6,
CEACAM-8 and CD99L2 adhesion molecules (Tables 4 and
S2) involved in the recruitment of neutrophils to vascular
endothelia. Functional studies should confirm whether those first
line-defence immune cells which produce an array of pro-
inflammatory mediators highly damaging to host tissues and
vascular endothelia [50,106], and poorly regarded in dengue
[107], definitively play a role in DSS pathophysiology.
Alteration of a gene pattern related to homeostasis of cholesterol
in monocytes/macrophages (Mo/Mac) in the blood cells of DSS
children (Table 5) was an unexpected finding, while it should be
considered regarding recent knowledge on the role of monocytes
as a pivotal link between inflammation, innate immunity and host
lipid metabolism [108,109]. Indeed, under physiological condi-
tions, monocytes maintain cholesterol homeostasis by clearing
modified LDL such as oxidized LDL (ox-LDL) from plasma.
Under pathological conditions, balance between uptake and efflux
of those modified cholesterol molecules may be altered
[59,60,62,66,67,86], resulting in the intracellular accumulation
of modified cholesterol. This turns classical monocytes towards a
pro-inflammatory phenotype, lipid-laden monocytes/macrophag-
es (Mo/Mac), a sub-type of pro-inflammatory immune cells
initially identified in vascular lesions of chronic inflammatory
metabolic diseases [110].
Recent knowledge has shown that those atypical monocytes
produce a large array of pro-inflammatory mediators such as
ROS, metalloproteases, eicosanoids, and pro-inflammatory adi-
pokines, making these cells potent contributors to vascular
damages, systemic inflammation and major metabolic changes
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PLoS ONE | www.plosone.org 11 July 2010 | Volume 5 | Issue 7 | e11671Figure 4. Hypothesis of a second inflammatory amplification loop in dengue shock syndrome. After induction of a first inflammatory and
anti-viral response to dengue virus, disease resolution generally occurs around time of defervescence for most dengue-infected patients. Some
patients however progress towards a life-threatening dengue shock syndrome. Results obtained in this study suggest that in those patients, a second
inflammatory amplification loop, which involves a diversity of pro-inflammatory responses related to innate immunity, occurs and leads to a major
inflammatory systemic syndrome and to vascular homeostasis breakdown. The putative role of different markers identified in vascular endothelial
dysfunction is indicated. Thin black arrow, release of; Bold black arrow, interaction between; Punctuated black arrow, chemotactic effect; Thin red
arrow, biological activity; Bold red arrow, direct activity on endothelium. DAMPs, danger-associated molecular pattern; GAG, glycosaminoglycane;
ROI, reactive oxygen intermediates; TLR, Toll-like receptor.
doi:10.1371/journal.pone.0011671.g004
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systemic inflammatory syndromes such as DSS or severe sepsis.
While the existence of functional lipid-laden Mo/Mac during DSS
should be established by functional studies, such a molecular
mechanism could explain decrease of circulating sub-fractions and
total cholesterol previously reported in DSS [112–115] and in
other critically ill patients where low cholesterol levels are
associated with poor clinical outcome [116,117].
Altered homeostasis of cholesterol in blood cells from DSS
patients could also favour replication of dengue viruses into host
cells [118], thus contributing to increased viremia in patients with
severe dengue infection [119,120], while this could not be
evaluated in this study since part of patients had undetectable
viremia at the time of blood sampling.
The factors contributing to altered homeostasis of cholesterol in
the blood cells of DSS children at time of shock are numerous.
Increased lipid peroxydation activity [113,114] insufficiently
compensated by anti-oxydant mechanisms [121], as supported
by related altered gene patterns identified in this study (Table 5),
may result in high levels of circulating ox-LDL contributing to
altered cholesterol metabolism. Differences in nutritional status
[122–124] or host genetics may also contribute to altered
homeostasis of cholesterol gene pattern in the blood cells of DSS
patients. Interestingly, transcripts encoding molecules considered
candidates to diseases characterized by impairment of cholesterol
homeostasis such as NPC1, PCSK9 and PPARG [66,67,74], have
significant altered abundance in the blood cells of DSS children
(Table 5). Further investigations should consider possible associ-
ations between DSS and allelic variants of such genes. Whatever
the determinants of cholesterol metabolism alterations in DSS
patients, our results reinforce interest in considering sub-fractions
and total cholesterol as putative biomarkers of DSS [115]. They
also suggest that drugs used to treat metabolic disorders such as
atherosclerosis should deserve further attention for the control of
such a pro-inflammatory process in dengue-infected patients, now
proposed for other critical illnesses [117].
Transcriptional activation of the lipid-related arachidonic acid
pathway in the whole blood cells of DSS children at the time of
shock was another pro-inflammatory mechanism relevant to the
pathophysiology of DSS [81]. Activation of this lipid metabolic
pathway in innate cells such as neutrophils or lipid-laden monocytes
during inflammatory process or infection [125], results in the
production of eicosanoid lipid mediators, that are not only
physiological regulators of vascular tone and permeability [81]
but also potent pro-inflammatory mediators involved in a number
of pathologies such as asthma [81]. Interestingly, formation of lipid
bodieswhereeicosanoidsynthesistakesplace,canbeinduced byox-
LDL through activation of the PPARc nuclear-lipid receptor [126],
thus suggesting a direct link between the three pro-inflammatory
pathways identified in DSS children and a contribution of
arachidonic pathway-related inflammatory lipids and oxidative
enzymes to the systemic vascular dysfunction leading to DSS.
Fourth, DAMPs and TLRs could be a link from primary to
secondary inflammation, leading to DSS. Occurrence of DSS in
only some patients at the late phase of infection is likely due to an
inadequate control or an amplification of the primary inflamma-
tory response aimed at fighting infection. The pro-inflammatory
molecular responses activated in the blood cells of DSS children at
time of shock involve a diversity of innate immune mediators that
may amplify a first-line inflammatory response mediated by TNF,
IL-6 or IL-1, thus contributing to a secondary inflammatory loop.
Indeed, a number of repair/remodeling and of defence gene
products over-expressed in DSS patients blood cells are considered
endogenous danger signals or Danger-Associated Molecular
Patterns (DAMPs) (Tables 3 and 4; molecules with DAMP activity
are indicated) capable to trigger secondary systemic inflammatory
responses through direct interaction with surface or intracellular
receptors such as TLRs or NODs expressed in endothelial or
innate immune cells [127]. DAMPs include a diversity of
molecules without structural similarity either actively produced
by immune cells in the context of an infection or passively secreted
by damaged tissues [128,129], now considered key inducers of
secondary systemic inflammation in a number of acute inflam-
matory syndromes [130,131] or chronic diseases [132].
Amplification of inflammation during DSS through direct
signalling by molecules harbouring DAMP activity via TLRs, is
also supported by the increased abundance of DAMP-induced
transcripts as those encoding the pro-inflammatory IL-18 cytokine
or the NLRC4/CARD12 intracellular sensor [55]. Interestingly,
association of allelic polymorphisms of TLR4 with DSS suggested
by De Kruif and colleagues [46] suggests that differential signalling
through TLRs may contribute to the severity of dengue disease, as
suspected for other pathologies [133]. Accordingly, anti-inflam-
matory drugs targeting Toll-like receptors are now under
development for a number of inflammatory pathologies where
innate immunity and TLRs play a central pathogenic role [134].
DSS pathophysiology: a secondary inflammatory loop
hypothesis
To summarize, we report the identification of a specific gene
expression profileinthe bloodcellsofDSSchildren attime ofshock,
characterizing DSS as a unique entity at the transcriptional level
whatever the immunological status of children regarding primary or
secondary infection. Major immunological alterations identified at
the time of shock are characterized by an altered balance between
depressed T lymphocyte responses and exacerbated compensatory
and pro-inflammatory innate immune responses that may, finally,
be detrimental to the host [135–137], while functional studies
should confirm the contribution of those molecular mechanisms to
DSS pathophysiology.
Based on recent knowledge on molecular mechanisms altered in
other systemic inflammatory diseases, DSS may result from a
complex pro-inflammatory network involving a diversity of innate
immune effectors sustaining a secondary systemic inflammatory
loop, leading in turn to vascular homeostasis breakdown and
systemic microcirculatory failure characterizing DSS (Figure 4).
We suggest that drugs available to treat metabolic and other
systemic chronic inflammatory diseases could be considered for
the treatment of dengue-infected patients before shock occurs, and
that a number of bio-markers found altered in DSS patients blood
cells should be evaluated. as putative predictive markers of
progression to DSS.
Supporting Information
Figure S1 Validation of microarray results by RT-PCR.
Pearson’s correlation was calculated between microarray expres-
sion signals (horizontal axis) and Delta Ct values from real-time
PCR (vertical axis) for nine genes highly associated to dengue
shock syndrome. ** Correlation is significant at 0.01.
Found at: doi:10.1371/journal.pone.0011671.s001 (4.94 MB TIF)
Table S1 Clinical and biological characteristics of each DF,
DHF and DSS patient
Found at: doi:10.1371/journal.pone.0011671.s002 (0.04 MB
XLS)
Table S2 List of the 3515 clones corresponding to the 2959
genes differentially expressed between DF, DHF and DSS
Molecular Mechanisms of DSS
PLoS ONE | www.plosone.org 13 July 2010 | Volume 5 | Issue 7 | e11671patients, identified using the multi-way ANOVA at a false
discovery rate of 10. Clones corresponding to the 2959 genes
are listed according to their association to DSS, the first one being
the gene of which expression level variance is the most influenced
by the clinical phenotype. HUGO gene names are indicated. The
variation is the one related to the DSS group relatively to DF and
DHF. ANOVA, analysis of variance; DF, dengue fever; DHF,
dengue hemorrhagic fever; DSS, dengue shock syndrome; NA, not
available. a percentage of variance associated to disease pheno-
type.
Found at: doi:10.1371/journal.pone.0011671.s003 (0.90 MB
XLS)
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